The U.S. Food and Drug Administration has approved a new cancer pill, Stivarga, from the drug manufacturer Bayer HealthCare. This particular prescription pill will be used in the treatment of gastrointestinal stromal tumors that cannot be surgically removed and won’t respond FDA-approved cancer drugs and treatments.
Stivarga had already been approved in the treatment of colorectal tumors, but it was also approved for intestinal tract cancers on Monday.
A study to prove Stivarga’s effectiveness included approximately 200 patients who were broken into two groups—one group took Stivarga and the second group was given a placebo.
Findings showed that patients taking Stivarga, which blocks several enzymes that promote cancer growth, experienced a delay of up to 4-months in the growth of their cancer tumors versus those taking the placebo.
Although the drug has proven effective in treating intestinal tumors, Bayer recognizes a few side effects uncovered during trails—including liver damage, peeling of skin, high blood pressure, heart attacks, severe bleeding, blistering, and perforations.
Source: Vancouver Sun